An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer. (Q46235194)
Jump to navigation
Jump to search
scientific article published in November 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer. |
scientific article published in November 2008 |
Statements
An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer (English)
B Parente
R Sotto-Mayor
E Teixeira
T Almodôvar
F Barata
H Queiroga
C Pereira
H Pereira
F Negreiro
1 November 2008